Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy

Supportive Care in Cancer

Volumn 22, Issue 6, 2014, Pages 1619-1628

  Choi, Mi Rim ^a   Solid, Craig A ^b   Chia, Victoria M ^a   Blaes, Anne H ^c   Page, John H ^a   Barron, Richard ^a   Arneson, Thomas J ^b  

^a AMGEN INC   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Elderly cancer patients; G CSF; G CSF patterns of use; Granulocyte colony stimulating factor; Supportive care; Treatment patterns

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PREDNISONE; RITUXIMAB; TOPOTECAN; TRASTUZUMAB; VINCRISTINE;

AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84902341215     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2121-7     Document Type: Article

References (26)

1. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158-3167 (Pubitemid 47218066)
2. Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555-5563
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Myeloid Growth Factors. V1.2012
4. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117:1917-1927
5. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205 (Pubitemid 46638957)
6. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Senior Adult Oncology. V2.2012
8. Du XL, Lairson DR, Begley CE, Fang S (2005) Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol 23:8620-8628 (Pubitemid 46211504)
9. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13:337-348 (Pubitemid 46958752)
10. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J (2011) Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 27:79-86
11. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402-407
12. Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G (2012) Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol 35:267-274
13. Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS (2009) Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 115:4839-4848
14. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916-1924 (Pubitemid 40563265)
15. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266 (Pubitemid 43673249)
16. Chen-Hardee S, Chrischilles EA, Voelker MD, Brooks JM, Scott S, Link BK, Delgado D (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 17:647-654 (Pubitemid 43668322)
17. Du XL, Osborne C, Goodwin JS (2002) Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642 (Pubitemid 36025279)
18. Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL (2010) Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. J Am Geriatr Soc 58:1885-1895
19. Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL (2011) Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy. Value Health 14:253-262
20. Rajan SS, Stearns SC, Lyman GH, Carpenter WR (2011) Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat 130:255-266
21. Repetto L, Biganzoli L, Koehne CH, Luebbe AS, Soubeyran P, Tjan- Heijnen VC, Aapro MS (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 39:2264-2272 (Pubitemid 37214850)
22. American Society of Clinical Oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508
23. Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427-437 (Pubitemid 40993570)
24. Baker J, McCune JS, Harvey RD 3rd, Bonsignore C, Lindley CM (2000) Granulocyte colony-stimulating factor use in cancer patients. Ann Pharmacother 34:851-857 (Pubitemid 30471265)
25. Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103:979-982
26. Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET (2000) Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol 18:1764-1770 (Pubitemid 30220556)